Inhibrx Biosciences, Inc. - INBX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | VIKING GLOBAL INVESTORS LP | 9.99% | 1,454,608 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Viking Global Opportunities Parent GP LLC | 9.99% | 1,454,608 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Viking Global Opportunities GP LLC | 9.3% | 1,351,744 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Viking Global Opportunities Portfolio GP LLC | 8.8% | 1,284,726 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Viking Global Opportunities Illiquid Investments Sub-Master LP | 8.8% | 1,284,726 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | KAVRA 104 LLC | 0.5% | 67,018 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Viking Global Opportunities Drawdown GP LLC | 0.7% | 102,864 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Viking Global Opportunities Drawdown Portfolio GP LLC | 0.7% | 102,864 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Viking Global Opportunities Drawdown (Aggregator) LP | 0.7% | 102,864 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | HALVORSEN OLE ANDREAS | 9.99% | 1,454,608 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Ott David C. | 9.99% | 1,454,608 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Shabet Rose Sharon | 9.99% | 1,454,608 | View |
| Feb 11, 2026 | SCHEDULE 13G | Morgan Stanley | 7.9% | 1,155,416 | View |
| Feb 11, 2026 | SCHEDULE 13G | Morgan Stanley Capital Services LLC | 6.3% | 918,011 | View |
| Jan 21, 2026 | SCHEDULE 13G | BlackRock, Inc. | 5.3% | 768,130 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.